Add BrightSurf on Google Email

Killer T cells could be recruited to ignite immune response against cancer, new study suggests

Researchers have discovered a way to bring cancer-killing T cells to bear against a specific type of colorectal cancer, showing promising results. The findings may represent a therapeutic strategy to target other types of cancers, and the next step is to further explore how T cells become activated in the tumor environment.

SourceUniversity of Alberta Faculty of Medicine & Dentistry·JournalJournal of Experimental Medicine·DateOct 8, 2021

Researchers at CNIO and 12 de Octubre Hospital prove efficacy of new immunotherapy for multiple myeloma

Researchers at CNIO and 12 de Octubre Hospital have developed a new cancer treatment called CAR-NK-cell immunotherapy, which uses natural killer cells to target cancerous cells. The treatment has shown promising results in mice with multiple myeloma, with 25% of treated mice remaining disease-free.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBlood Cancer Journal·TypeExperimental study·DateOct 6, 2021

Antidepressants inhibit cancer growth in mice

Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.

SourceUniversity of Zurich·JournalScience Translational Medicine·DateSep 28, 2021

Researchers report on new way to deliver healing stem cells to kidney injury patients

A new ex vivo drug delivery system has been shown to keep MSCs viable longer and reprogram the peripheral immune response toward organ repair. The study's results suggest that SBI-101 can impact a peripheral immune response that can be transmitted to local tissue damage in vital organs, including the kidney.

SourceAlphaMed Press·JournalStem Cells Translational Medicine·TypeRandomized controlled/clinical trial·DateSep 28, 2021

New nano particles suppress resistance to cancer immunotherapy

Scientists at Hokkaido University have developed a lipid nanoparticle that delivers immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy. This approach has shown promise in mice experiments and could lead to the development of an adjuvant treatment for cancer patients.

SourceHokkaido University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateSep 17, 2021

Patients treated with immune checkpoint inhibitors have better quality of life, Moffitt analysis shows

Patients treated with immune checkpoint inhibitors show better quality of life and reduced symptoms compared to those without immunotherapy. The study analyzed self-reported outcomes of 26 published studies and found that patients' global quality of life was stable or improved, but breathing difficulties increased

Cancer immunotherapy gets PIP boost

Researchers at Kyoto University designed a synthetic molecular code, EnPGC-1, that activates mitochondrial biogenesis in T cells, increasing their numbers and longevity. The approach enhances anti-tumor immunity in mice and improves survival.

SourceKyoto University·JournalCell Chemical Biology·DateSep 13, 2021

Older patients benefit from cancer immunotherapies

Researchers analyzed large datasets to find biomarkers that could help select immunotherapy treatment for older patients. The analysis suggests that factors such as mutational burden and immune checkpoint protein expression are associated with increased response to immunotherapies in older patients, despite lower general immunity.

SourceJohns Hopkins Medicine·JournalCell Reports·DateSep 7, 2021

Many with food allergies don’t know about oral immunotherapy treatment option

A nationally representative survey found that 72% of people with food allergies were unaware of oral immunotherapy as a treatment option. The study highlights the need for more accessible and equitable outreach efforts to ensure all patients can benefit from recent advances in food allergy treatments.

SourceAnn & Robert H. Lurie Children's Hospital of Chicago·JournalJournal of Allergy and Clinical Immunology·DateSep 2, 2021

Increased survival with eye melanoma in clinical trial

A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.

SourceUniversity of Gothenburg·JournalNature Communications·TypeRandomized controlled/clinical trial·DateAug 30, 2021

A more complete molecular picture of lung squamous cell carcinoma comes into view

A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.

SourceBroad Institute of MIT and Harvard·JournalCell·TypeComputational simulation/modeling·DateAug 5, 2021

Cancer treatments didn’t falter in Australia during 2020 COVID-19 lockdowns

A big data study from UNSW Sydney found that Australian cancer patients kept up their pharmaceutical treatments during last year's COVID-19 lockdowns. The researchers attribute the good news to relatively low rates of COVID-19 infections in Australia, which minimally impacted cancer treatment patterns.

SourceUniversity of New South Wales·JournalThe Lancet Regional Health - Western Pacific·TypeData/statistical analysis·DateAug 3, 2021

Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer

Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.

SourceMichigan Medicine - University of Michigan·JournalNature Cancer·TypeExperimental study·DateAug 2, 2021

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status

Researchers found that patients with advanced bladder cancers and FGFR3 mutations respond to immunotherapy just like those without the mutation. The study's findings suggest that FGFR3-mutated tumors can benefit from immunotherapy treatment, providing a new option for patients who previously had limited treatment options.

SourceUNC Lineberger Comprehensive Cancer Center·JournalBritish Journal of Cancer·DateJul 22, 2021

Cancer: Immunotherapies without side effects?

Researchers from UNIGE and Harvard Medical School have discovered the difference between desired immune responses targeting cancer cells and unwanted responses affecting healthy tissue. By understanding these differences, they aim to develop new therapeutic approaches that minimize toxic side effects and maximize treatment efficacy.

SourceUniversité de Genève·JournalScience Immunology·DateJul 2, 2021

Closer to cure: New imaging method tracks cancer treatment efficacy in preclinical studies

Researchers develop a non-invasive imaging method to track IDO1 activity, providing a promising alternative to invasive biopsies. The study found that IDO1 status in the mesenteric lymph node is a surrogate marker for cancer-immune set point and predicts immunotherapeutic efficacy.

SourceThe National Institutes for Quantum Science and Technology·JournalJournal for ImmunoTherapy of Cancer·DateJul 2, 2021

Anti-cancer immunotherapy drug with reduced side effects and increased therapeutic effects

Researchers have developed an anti-cancer prodrug that targets cancer cells while minimizing toxicity to normal cells. This innovation improves the effectiveness of immunotherapy by boosting patient immunity. The drug exhibits anticancer effects when activated in cancer cells, inducing an active anticancer immune response.

Combining immunotherapies against cancer

Researchers developed a microparticle-based cancer vaccine that kickstarts an immune response, increasing the proportion of mice cured of tumors to 75%. Combining the vaccine with immune checkpoint inhibitors greatly improves treatment success, offering a promising approach to improving cancer treatment.

SourceUniversity of Konstanz·JournalNature Communications·DateMay 18, 2021

Bacteria may aid anti-cancer immune response

Researchers have discovered that bacteria residing within tumor cells can be harnessed to provoke an immune reaction against the tumor. The findings suggest that bacterial peptides presented on tumor cells can serve as potential targets for immunotherapy, enabling immune T cells to recognize and attack cancer cells more precisely.

Sequential treatment with immunotherapy and checkpoint inhibitors prolongs anti-tumor activity

Researchers at Moffitt Cancer Center found that sequential treatment with immunotherapy followed by BRAF and MEK inhibitors promotes anti-tumor immunity and suppresses signaling that leads to drug resistance. The study suggests that this approach may be a potential treatment option for patients with melanoma.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalCancer Immunology Research·DateMar 2, 2021